Loading...
•
Jun 30, 2022
Paysign Q2 2022 Earnings Report
Paysign's financial performance improved with increased revenue, improved margins, and onboarding of a record number of new plasma donation centers.
Key Takeaways
Paysign reported strong Q2 2022 results with improvements in top and bottom lines and gross margins. The company onboarded a record number of new plasma donation centers and expects revenue to grow 27.5% over 2021.
Improved top and bottom lines.
Increased gross margins.
Onboarded a record number of new plasma donation centers.
Expects revenue to grow 27.5% over 2021.
Forward Guidance
Paysign anticipates continued revenue growth, driven primarily by its plasma business, with total revenue expected to grow 27.5% over 2021. Full-year gross profit margins are expected to be between 56% and 57%. Adjusted EBITDA is expected to be $4.7 million to $5.3 million.
Positive Outlook
- Total revenue to grow 27.5% over 2021.
- Plasma is estimated to make up about 92% of total revenues for 2022.
- Full-year gross profit margins are expected to be between 56% and 57%.
- Q3 2022 total revenues to be approximately $10.2 million.
- Q4 2022 total revenues to be approximately $10.5 million.
Challenges Ahead
- Two pharma prepaid programs ending in mid-November.
- Operating expenses expected to be approximately $22.0 million.
- Q3 2022 Adjusted EBITDA being slightly higher than Q4 2022 due to the end of the pharma prepaid programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...